Bioactive Benzofuran derivatives: A review

European Journal of Medicinal Chemistry

Volumn 97, Issue 1, 2015, Pages 483-504

  Khanam, Hena ^a   Shamsuzzaman, ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Antimicrobial; Antitumor; Benzofurans; Heterocycles Antiviral

Indexed keywords

ANALGESIC AGENT; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXYTOCIN ANTAGONIST; PEPTIDE DEFORMYLASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; BENZOFURAN;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIPYRETIC ACTIVITY; ANTIVIRAL ACTIVITY; BREAST CARCINOMA; COLON CARCINOMA; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHARMACOPHORE; REVIEW; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOFURANS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84934924600     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.11.039     Document Type: Review

References (210)

1. V. Polshettiwar, R.S. Varma, Greener and sustainable approaches to the synthesis of pharmaceutically active heterocycles, Curr. Opin. Drug Discov. Devel 10 (2007) 723-737.
2. A. Padwa, S.K. Bur, The domino way to heterocycles, Tetrahedron 63 (2007) 5341-5378.
3. D.M. D'Souza, T.J. Muller, Multi-component syntheses of heterocycles by transition-metal catalysis, Chem. Soc. Rev. 36 (2007) 1095-1108.
4. G. Eren, S. Unlu, M.T. Nunez, L. Labeaga, F. Ledo, A. Entrena, E.B. Lu, G. Costantino, M.F. Sahin, Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors, Bioorg. Med. Chem. 18 (2010) 6367-6376.
5. J.D. Hepworth, in: A.J. Boulton, A. McKillop (Eds.), Comprehensive Heterocyclic Chemistry, 3, Pergamon Press, Oxford, 1984, pp. 835-840.
6. E. Gordon, R.W. Barrett, W.J. Dower, S.P. Foder, A. Gallop Mark, Applications of combinatorial technologies to drug discovery 2. Combinatorial organic synthesis, library screening strategies, and future directions, J. Med. Chem. 37 (1994) 1385-1401.
7. N.A. McGrath, M. Brichacek, J.T. Njardarson, A graphical journey of innovative organic architectures that have improved our lives, J. Chem. Educ. 87 (2010) 1348-1349.
8. P.D. Leeson, B. Springthorpe, The influence of drug-like concepts on decision making in medicinal chemistry, Nat. Rev. Drug Discov. 6 (2007) 881-890.
9. R.W. DeSimone, K.S. Currie, S.A. Mitchell, J.W. Darrow, D.A. Pippin, Privileged structures: applications in drug discovery, Comb. Chem. High. Throughput Screen. 7 (2004) 473-494.
10. S.A. Hayta, M. Arisoy, O.T. Arpaci, I. Yildiz, E. Aki, S. Ozkan, F. Kaynak, Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5 [(2-benzofuryl) carboxamido] benzoxazoles, Eur. J. Med. Chem. 43 (2008) 2568-2578.
11. M. Kamal, A.K. Shakya, T. Jawaid, Benzofurans: a new profile of biological activities, Int. J. Med. Pharm. Sci. 1 (2011) 1-15.
12. B. Cottineau, P. Toto, C. Marot, A. Pipaud, J. Chenault, Synthesis and hypoglycemic evaluation of substituted pyrazole-4-carboxylic acids, Bioorg. Med. Chem. Lett. 12 (2002) 2105-2108.
13. Y.-S. Xie, D. Kumar, V.D.V. Bodduri, P.S. Tarani, B.-X. Zhao, J.-Y. Miao, K. Jang, D.-S. Shin, Microwave-assisted parallel synthesis of benzofuran-2-carboxamide derivatives bearing anti-inflammatory, analgesic and antipyretic agents, Tetrahedron Lett. 55 (2014) 2796-2800.
14. M. Th-evenin, S. Thoret, P. Grellier, J. Dubois, Synthesis of polysubstituted benzofuran derivatives as novel inhibitors of parasitic growth, Bioorg. Med. Chem. 21 (2013) 4885-4892.
15. M. Koca, S. Servi, C. Kirilmis, M. Ahmedzade, C. Kazaz, B. Ozbek, G. Otük, Synthesis and antimicrobial activity of some novel derivatives of benzofuran: part 1. synthesis and antimicrobial activity of (benzofuran-2-yl)(3-phenyl-3-methylcyclobutyl) ketoxime derivatives, Eur. J. Med. Chem. 40 (2005) 1351-1358.
16. F. Xie, H. Zhu, H. Zhang, Q. Lang, L. Tang, Q. Huang, L. Yu, In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel aurora B kinase inhibitor, Eur. J. Med. Chem. 89 (2015) 310-319.
17. O. Oter, K. Ertekin, C. Kirilmis, M. Koca, M. Ahmedzade, Characterization of a newly synthesized fluorescent benzofuran derivative and usage as a selective fiber optic sensor for Fe(III), Sens. Actuators B: Chem. 122 (2007) 450-456.
18. F. Karatas, M. Koca, H. Kara, S. Servi, Synthesis and oxidant properties of novel (5-bromobenzofuran-2-yl)(3-methyl-3-mesitylcyclobutyl) ketonethiosemicarbazone, Eur. J. Med. Chem. 41 (2006) 664-669.
19. J. Habermann, S.V. Ley, R. Smits, Three-step synthesis of an array of substituted benzofurans using polymer-supported reagents, J. Chem. Soc. Perkin Trans. 1 (1999) 2421-2423.
20. Y.W. Kim, H.D. Choi, P.J. Seo, B.W. Son, Synthesis of 2-arylbenzofuran derivatives using x-(methylsulfinyl) acetophenone, J. Korean Chem. Soc. 45 (2001) 391-394.
21. C.L. Kao, J.W. Chern, A convenient synthesis of naturally occurring benzofuran ailanthoidol, Tetrahedron Lett. 42 (2001) 1111-1113.
22. M. Spaniol, R. Bracher, H.R. Ha, F. Follath, S. Kralhenbühl, Toxicity of amiodarone analogs on isolated rat liver mitochondria, J. Hepatol. 35 (2001) 628-636.
23. S. Narimatsu, C. Takemi, S. Kuramoto, D. Tsuzuki, H. Hichiya, K. Tamagake, S. Yamamoto, Stereoselectivity in the oxidation of Bufuralol, a chiral substrate, by human cyctochrome P450s, Chirality 15 (2003) 333-339.
24. J.C.G.-Gomez, L. Santana, E. Uriarte, A furan ring expansion approach to the synthesis of novel pyridazino-psoralen derivatives, Tetrahedron 61 (2005) 4805-4810.
25. P. Nore, E. Honkanen, A new synthesis of methoxalen, J. Heterocycl. Chem. 17 (1980) 985-987.
26. L. De Luca, G. Nieddu, A. Porcheddu, G. Giacomelli, Some recent approaches to the synthesis of 2-substituted benzofurans, Curr. Med. Chem. 16 (2009) 1-20.
27. F.V. Singh, T. Wirth, Hypervalent iodine mediated oxidative cyclization of Ohydroxystilbenes into benzo-and naphthofurans, Synthesis 44 (2012) 1171-1177.
28. C. Eidamshaus, J.D. Burch, One-pot synthesis of benzofurans via palladiumcatalyzed enolate arylation with O-bromophenols, Org. Lett. 10 (2008) 4211-4214.
29. W.A.L. van Otterlo, G.L. Morgans, L.G. Madeley, S. Kuzvidza, S.S. Moleele, N. Thornton, C.B. de Koning, An isomerization-ring-closing metathesis strategy for the synthesis of substituted benzofurans, Tetrahedron 61 (2005) 7746-7755.
30. A.V.-Fern-andez, C.G.-Rodríguez, J.A. Varela, L. Castedo, C. Sa-a, Cycloisomerization of aromatic homo-and bis-homopropargylic alcohols via catalytic Ru vinylidenes: formation of benzofurans and isochromenes, Org. Lett. 11 (2009) 5350-5353.
31. S.E. Denmark, R.C. Smith, W.-T.T. Chang, J.M. Muhuhi, Cross-coupling reactions of aromatic and heteroaromatic silanolates with aromatic and heteroaromatic halides, J. Am. Chem. Soc. 131 (2009) 3104-3118.
32. X. Wang, M. Liu, L. Xu, Q. Wang, J. Chen, J. Ding, H. Wu, Palladium-catalyzed addition of potassium aryltrifluoroborates to aliphatic nitriles: synthesis of alkyl aryl ketones, diketone compounds, and 2-arylbenzo [b]furans, J. Org. Chem. 78 (2013) 5273-5281.
33. D.-H. Lee, K.-H. Kwon, C.S. Yi, Dehydrative C-H alkylation and alkenylation of phenols with alcohols: expedient synthesis for substituted phenols and benzofurans, J. Am. Chem. Soc. 134 (2012) 6571-6574.
34. F. Contiero, K.M. Jones, E.A. Matts, A. Porzelle, N.C.O. Tomkinson, Direct preparation of benzofurans from O-arylhydroxylamines, Synlett (2009) 3003-3006.
35. L. De Luca, G. Giacomelli, G. Nieddu, A facile approach to the synthesis of chiral 2-substituted benzofurans, J. Org. Chem. 72 (2007) 3955-3957.
36. D. Yue, T. Yao, R.C. Larock, Synthesis of 2, 3-disubstituted benzo [b]furans by the palladium-catalyzed coupling of O-iodoanisoles and terminal alkynes, followed by electrophilic cyclization, J. Org. Chem. 70 (2005) 10292-10296.
37. H. Varmus, The new era in cancer research, Science 312 (2006) 1162-1165.
38. J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray, GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], International Agency for Research on Cancer, Lyon, France, 2013. Available from: http://globocan.iarc.fr (accessed December 2013).
39. C.M. Haskell, Cancer treatment, W.B. Saunders Company, Philadelphia, 2001.
40. S.V. Miert, S.V. Dyck, T.J. Schmidt, R. Brun, A. Vlietinck, G. Lemiere, L. Pieters, Antileishmanial activity, cytotoxicity and QSAR analysis of synthetic dihydrobenzofuran lignans and related benzofurans, Bioorg. Med. Chem. 13 (2005) 661-669.
41. G.N. Zhang, L.Y. Zhong, S.W.A. Bligh, Y.L. Guo, C.F. Zhang, M. Zhang, Z.T. Wang, L.S. Xu, Bi-bicyclic and bi-tricyclic compounds from dendrobium thyrsiflorum, Phytochemistry 66 (2005) 1113-1120.
42. W.-C. Wan, W. Chen, L.-X. Liu, Y. Li, L.-J. Yang, X.-Y. Deng, H.-Bin Zhang, X.-D. Yang, Synthesis and cytotoxic activity of novel hybrid compounds between 2-alkylbenzofuran and imidazole, Med. Chem. Res. 23 (2014) 1599-1611.
43. M. Hranjec, I. Sovic, I. Ratkaj, G. Pavlovic, N. Ilic, L. Valjalo, K. Pavelic, S.K. Pavelic, G.K.-Zamola, Antiproliferative potency of novel benzofuran-2-carboxamides on tumour cell lines: cell death mechanisms and determination of crystal structure, Eur. J. Med. Chem. 59 (2013) 111-119.
44. S. Clarke, Protein isoprenylation and methylation at carboxyl-terminal cysteine residues, Annu. Rev. Biochem. 61 (1992) 355-386;
45. A.D. Cox, C.J. Der, The ras/cholesterol connection: implications for ras oncogenicity, Crit. Rev. Oncog. 3 (1992) 365-400.
46. F. Tamanoi, J.K.-Stankiewicz, C. Jiang, I. Machado, N. Thapar, Farnesylated proteins and cell cycle progression, Cell. Biochem. Suppl. 37 (2001) 64-70.
47. D.M. Leonard, Ras Farnesyltransferase: a new therapeutic target, J. Med. Chem. 40 (1997) 2971-2990;
48. S.M. Sebti, A.D. Hamilton, New approaches to anticancer drug design based on the inhibition of farnesyltransferase, Drug Discov. Today 3 (1998) 26-33.
49. K. Asoh, M. Kohchi, I. Hyoudoh, T. Ohtsuka, M. Masubuchi, K. Kawasaki, H. Ebiike, Y. Shiratori, T.A. Fukami, O. Kondoh, T. Tsukaguchi, N. Ishii, Y. Aoki, N. Shimma, M. Sakaitani, Synthesis and structureeactivity relationships of novel benzofuran farnesyltransferase inhibitors, Bioorg. Med. Chem. Lett. 19 (2009) 1753-1757.
50. Assay methods described in: M. Sakaitani, K. Masubuchi, M. Kohchi, I. Hyoudoh, K. Asoh, M. Asai, WO Patent 04/037816, 2004.
51. B.R. Zetter, Angiogenesis and tumor metastasis, Annu. Rev. Med. 49 (1998) 407-424;
52. P. Carmeliet, R.K. Jain, Angiogenesis in cancer and other diseases, Nature 407 (2000) 249-257;
53. J. Folkman, Role of angiogenesis in tumor growth and metastasis, Semin. Oncol. 29 (2002) 15-18.
54. C. Unger, New therapeutic approaches in cancer treatment, Drugs Future 22 (1997) 1337-1345.
55. J.M. Hur, J.S. Shim, H.J. Jung, H.J. Kwon, Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro, Exp. Mol. Med. 37 (2005) 133-137.
56. S. Apers, D. Paper, J. Bürgermeister, S. Baronikova, S.V. Dyck, G. Lemi-ere, A. Vlietinck, L. Pieters, Antiangiogenic activity of synthetic dihydrobenzofuran lignans, J. Nat. Prod. 65 (2002) 718-720.
57. H. Ogura, T.N.-Ueda, T. Ueda, S. Iwai, S. Uchida, Y. Saito, Y. Taguchi, H. Yasuhara, D. Armstrong, K. Oguchi, R. Koide, Effect of a dihydrobenzofuran derivative on lipid hydroperoxide-induced rabbit corneal neovascularisation, J. Pharmacol. Sci. 103 (2007) 234-240;
58. M. Saito, M. Ueo, S. Kametaka, O. Saigo, S. Uchida, H. Hosaka, K. Sakamoto, T. Nakahara, A. Mori, K. Ishii, Attenuation of cataract progression by A-3922, a dihydrobenzofuran derivative, in streptozotocin-induced diabetic rats, Biol. Pharm. Bull. 31 (2008) 1959-1963.
59. Y. Chen, S. Chen, X. Lu, H. Cheng, Y. Oua, H. Cheng, G.-C. Zhou, Synthesis, discovery and preliminary SAR study of benzofuran derivatives as angiogenesis inhibitors, Bioorg. Med. Chem. Lett. 19 (2009) 1851-1854.
60. N.S. Magnuson, Z. Wang, G. Ding, R. Reeves, Why target PIM1 for cancer diagnosis and treatment Future Oncol. 6 (2010) 1461-1478;
61. M.C. Nawijin, A. Alendar, A. Berns, For better or for worse: the role of pim oncogenes in tumorigenesis, Nat. Rev. Cancer 11 (2011) 23-34.
62. H.T. Cuypers, G. Selten, W. Quint, M. Zijlstra, E.R.-Manndag, W. Boelens, P. Van Wezenbeek, A. Berns, Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region, Cell 37 (1984) 141-150.
63. R. Amson, F. Sigaux, S. Przedborski, G. Flandrin, D. Givol, A. Telerman, The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias, Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 8857-8861.
64. A.M. Cohen, B. Grinblat, H. Bessler, D. Kristt, A. Kremer, A. Schwartz, M. Halperin, S. Shalom, D. Merkel, J. Don, Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma, Leuk. Lymphoma 45 (2004) 951-955.
65. Z.F. Tao, L.A. Hasvold, J.D. Leverson, E.K. Han, R. Guan, E.F. Johnson, V.S. Stoll, K.D. Stewart, G. Stamper, N. Soni, J.J. Bouska, Y. Luo, T.J. Sowin, N.H. Lin, V.S. Giranda, S.H. Rosenberg, T.D. Penning, Discovery of 3H-benzo [4, 5] thieno [3, 2-d] pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases, J. Med. Chem. 52 (2009) 6621-6636;
66. A.C. Pierce, M. Jacobs, C.S.-Moody, Docking study yields four novel inhibitors of the protooncogene pim-1 kinase, J. Med. Chem. 51 (2008) 1972-1975.
67. Y. Xiang, B. Hirth, G. Asmussen, H.-P. Biemann, K.A. Bishop, A. Good, M. Fitzgerald, T. Gladysheva, A. Jain, K. Jancsics, J. Liu, M. Metz, A. Papoulis, R. Skerlj, J.D. Stepp, R.R. Wei, The discovery of novel benzofuran-2-carboxylic acids as potent pim-1 inhibitors, Bioorg. Med. Chem. Lett. 21 (2011) 3050-3056.
68. A. Castonguay, C. Doucet, M. Juhas, D. Maysinger, New Ruthenium(II)e Letrozole complexes as anticancer therapeutics, J. Med. Chem. 55 (2012) 8799-8806.
69. J. Russo, I.H. Russo, The role of estrogen in the initiation of breast cancer, J. Steroid Biochem. Mol. Biol. 102 (2006) 89-96.
70. S. Nilsson, S. Makela, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, J.-A. Gustafsson, Mechanisms of estrogen action, Physiol. Rev. 81 (2001) 1535-1565.
71. B.J. Kennedy, Hormone therapy for advanced breast cancer, Cancer 18 (1965) 1551-1557.
72. V.C. Jordan, A.M.H. Brodie, Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer, Steroids 72 (2007) 7-25.
73. V.C. Jordan, Tamoxifen: a most unlikely pioneering medicine, Nat. Rev. Drug Disc. 2 (2003) 205-213.
74. E. Coezy, J.L. Borgna, H. Rochefort, Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth, Cancer Res. 42 (1982) 317-323.
75. T.A.R.-Hellekant, A.J. Skildum, O. Zhdankin, A.L. Greene, R.R. Regal, K.D. Kundel, D.W. Kundel, Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptorepositive/progesterone receptorenegative mammary tumors, Cancer Prev. Res. 2 (2009) 496-502.
76. X.-Y. Li, Bi-F. He, H.-J. Luo, N.-Y. Huang, W.-Q. Deng, 3-Acyl-5-hydroxybenzofuran derivatives as potential anti-estrogen breast cancer agents: a combined experimental and theoretical investigation, Bioorg. Med. Chem. Lett. 23 (2013) 4617-4621.
77. S. Honore, E. Pasquier, D. Braguer, Understanding microtubule dynamics for improved cancer therapy, Cell. Mol. Life. Sci. 62 (2005) 3039-3056;
78. B.R. Hearn, S.J. Shaw, D.C. Myles, Microtubule targeting agents, Comp. Med. Chem. II 7 (2006) 81-110;
79. E. Pasquier, N. Andr-e, D. Braguer, Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment, Curr. Cancer Drug Target 7 (2007) 566-581.
80. R. Romagnoli, P.G. Baraldi, M.D. Carrion, C.L. Cara, O.C.-Lopez, M. Tolomeo, S. Grimaudo, A. Di Cristina, M.R. Pipitone, J. Balzarini, N. Zonta, A. Brancale, E. Hamel, Design, synthesis and structureeactivity relationship of 2-(3, 4, 5-trimethoxybenzoyl)-benzo [b] furan derivatives as a novel class of inhibitors of tubulin polymerization, Bioorg. Med. Chem. 17 (2009) 6862-6871.
81. L. Pieters, S.V. Dyck, M. Gao, R. Bai, E. Hamel, A. Vlietinck, G. Lemie're, Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerization, J. Med. Chem. 42 (1999) 5475-5481.
82. J.R. Woodgett, Molecular cloning and expression of glycogen synthase kinase-3/factor A, EMBO J. 9 (1990) 2431-2438.
83. I.N. Gaisina, F. Gallier, A.V. Ougolkov, K.H. Kim, T. Kurome, S. Guo, D. Holzle, D.N. Luchini, S.Y. Blond, D.D. Billadeau, A.P. Kozikowski, From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl) maleimides as glycogen synthase kinase 3b inhibitors that suppress proliferation and survival of pancreatic cancer cells, J. Med. Chem. 52 (2009) 1853-1863.
84. D. Fan, T.J. Beltran, C.A. O'Brien, Reversal of multidrug resistance, in: J.A. Kellen (Ed.), Reversal of Multidrug Resistance in cancer, CRC Press, Boca Raton, FL, 1994.
85. R.L. Juliano, V. Ling, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochim. Biophys. Acta. 455 (1976) 152-162.
86. J.A. Kellen, Multidrug resistance, in: J.A. Kellen (Ed.), Reversal of Multidrug Resistance in cancer, CRC Press, Boca Raton, FL, 1994, pp. 1-19.
87. J.M. Ford, W.N. Hait, Pharmacology of drugs that alter multidrug resistance in cancer, Pharmacol. Rev. 42 (1990) 155-199.
88. P. Chiba, S. Burghofer, E. Richter, B. Tell, A. Moser, G. Ecker, Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance, J. Med. Chem. 38 (1995) 2789-2793.
89. G. Ecker, P. Chiba, M. Hitzler, D. Schmid, K. Visser, H.P. Cordes, J. Csollei, J.K. Seydel, K.-J. Schaper, Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance, J. Med. Chem. 39 (1996) 4767-4774.
90. S. Parekh, D. Bhavsar, M. Savant, S. Thakrar, A. Bavishi, M. Parmar, H. Vala, A. Radadiya, N. Pandya, J. Serly, J. Moln-ar, A. Shah, Synthesis of some novel benzofuran-2-yl(4, 5-dihyro-3, 5-substituted diphenylpyrazol-1-yl) methanones and studies on the antiproliferative effects and reversal of multidrug resistance of human MDR1-gene transfected mouse lymphoma cells in vitro, Eur. J. Med. Chem. 46 (2011) 1942-1948.
91. M.D. Lee, Y. She, M.J. Soskis, C.P. Borella, J.R. Gardner, P.A. Hayes, B.M. Dy, M.L. Heaney, M.R. Philips, W.G. Bornmann, F.M. Sirotnak, D.A. Scheinberg, Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics, J. Clin. Invest 114 (2004) 1107-1116.
92. C. Antczak, D. Shum, B. Bassit, M.G. Frattini, Y. Li, E. de Stanchina, D.A. Scheinberg, H. Djaballah, Identification of benzofuran-4, 5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase, Bioorg. Med. Chem. Lett. 21 (2011) 4528-4532.
93. M.E. Welker, G. Kulik, Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors, Bioorg. Med. Chem. 21 (2013) 4063-4091.
94. S. Cao, W. Zhong, Biological function and inhibitors of mTOR: research advances, J. Int. Pharm. Res. 41 (2014) 6-20.
95. T.R. Kau, F. Schroeder, S. Ramaswamy, C.L. Wojciechowski, J.J. Zhao, T.M. Roberts, J. Clardy, W.R. Sellers, P.A. Silver, A chemical genetic screen identifies inhibitors of regulated nuclear export of a forkhead transcription factor in PTEN-deficient tumor cells, Cancer Cell. 4 (2003) 463-476.
96. I. Smukste, B.R. Stockwell, Restoring functions of tumor suppressors with small molecules, Cancer Cell. 4 (2003) 419-420.
97. C. Salom-e, V. Narbonne, N. Ribeiro, F. Thuaud, M. Serova, A. de Gramont, S. Faivre, E. Raymond, L. D-esaubry, Benzofuran derivatives as a novel class of inhibitors of mTOR signaling, Eur. J. Med. Chem. 74 (2014) 41-49.
98. C. Salom-e, N. Ribeiro, T. Chavagnan, F. Thuaud, M. Serova, A. de Gramont, S. Faivre, E. Raymond, L. D-esaubry, Benzofuran derivatives as anticancer inhibitors of mTOR signalling, Eur. J. Med. Chem. 81 (2014) 181-191.
99. S. Rachakonda, L. Cartee, Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics, Curr. Med. Chem. 11 (2004) 775-793.
100. C. Nathan, Antibiotics at the crossroads, Nature 431 (2004) 899-902.
101. R. Leclercq, Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci, Clin. Microbiol. Infect. 15 (2009) 224-231.
102. K. Manna, Y.K. Agrawal, Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs, Eur. J. Med. Chem. 45 (2010) 3831-3839.
103. M. BraEndvang, V. Bakken, L.-L. Gundersen, Synthesis, structure, and antimycobacterial activity of 6 [1(3H)-isobenzofuranylidenemethyl] purines and analogs, Bioorg. Med. Chem. Lett. 17 (2009) 6512-6516.
104. V.N. Telveka, A. Belubbi, V.K. Bairwa, K. Satardekar, Novel N-benzylidene benzofuran-3-carbohydrazide derivatives as antitubercular and antifungal agents, Bioorg. Med. Chem. Lett. 22 (2012) 2343-2346.
105. T. Yempala, J.P. Sridevi, P. Yogeeswari, D.S.S. Kantevari, Design, synthesis and antitubercular evaluation of novel 2-substituted-3H-benzofuro benzofurans via palladiumecopper catalysed sonagashira coupling reaction, Bioorg. Med. Chem. Lett. 23 (2013) 5393-5396.
106. S.H. Mehdi, R. Hashim, R.M. Ghalib, M. F-atima, C.G. da Silva, O. Sulaiman, S.Z. Rahman, V. Murugaiyah, M.M. Marimuthu, Synthesis, characterization, antimicrobial and enzymatic activity of 4b, 9b dihydroxy-7, 8-dihydro-4bHindeno [1, 2-b] benzofuran-9, 10 (6H, 9bH)-dione, J. Mol. Str. 1006 (2011) 318-323.
107. C. Kirilmis, M. Ahmedzade, S. Servi, M. Koca, A. Kizirgil, C. Kazaz, Synthesis and antimicrobial activity of some novel derivatives of benzofuran: Part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2 mesitylethanone derivatives, Eur. J. Med. Chem. 43 (2008) 300-308.
108. X. Jiang, W. Liu, W. Zhang, F. Jiang, Z. Gao, H. Zhuang, L. Fu, Synthesis and antimicrobial evaluation of new benzofuran derivatives, Eur. J. Med. Chem. 46 (2011) 3526-3530.
109. B.F. Abdel-Wahab, H.A. Abdel-Aziz, E.M. Ahmed, Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4, 5-dihydro-5-aryl-1 [4-(aryl)-1, 3-thiazol-2-yl]-1H-pyrazoles, Eur. J. Med. Chem. 44 (2009) 2632-2635.
110. J. Liu, F. Jiang, X. Jiang, W. Zhang, J. Liu, W. Liu, L. Fu, Synthesis and antimicrobial evaluation of 3-methanone-6-substituted benzofuran derivatives, Eur. J. Med. Chem. 54 (2012) 879-886.
111. K. Manna, Y.K. Agrawal, Microwave assisted synthesis of new indophenazine 1, 3, 5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity, Bioorg. Med. Chem. Lett. 19 (2009) 2688-2692.
112. R.W. Middleton, J. Parrick, in: S. Patak, Z. Rappoport (Eds.), The Chemistry of the Quinonoid Compounds, John Wiley & Sons, London, 1988, pp. 1019-1066.
113. Ch-K. Ryu, A.L. Song, J.Y. Lee, J.A. Hong, J.H. Yoon, A. Kim, Synthesis and antifungal activity of benzofuran-5-ols, Bioorg. Med. Chem. Lett. 20 (2010) 6777-6780.
114. M.-A. Bazin, L. Bodero, C. Tomasoni, B. Rousseau, C. Roussakis, P. Marchand, Synthesis and antiproliferative activity of benzofuran-based analogs of cercosporamide against non-small cell lung cancer cell lines, Eur. J. Med. Chem. 69 (2013) 823-832.
115. Z. Wang, H. Elokdah, G. McFarlane, S. Pan, M. Antane, Regioselective suzuki coupling of benzofuran or benzothiophene boronic acids and dibromo substituted naphthalenes: synthesis of a potent inhibitor of plasminogen activator inhibitor-1, Tetrahedron Lett. 47 (2006) 3365-3369.
116. P. Castaneda, L. Gomez, R. Mata, B. Lotina-Hennsen, A.L. Anaya, R. Bye, Phytogrowth-inhibitory and antifungal constituents of helianthella quinquenervis, J. Nat. Prod. 59 (1996) 323-326.
117. N. Gundogdu-Karaburun, K. Benkli, Y. Tunali, U. Ucucu, S. Demirayak, Synthesis and antifungal activities of some aryl [3-(imidazol-1-yl/triazol-1-ylmethyl) benzofuran-2-yl] ketoximes, Eur. J. Med. Chem. 41 (2006) 651-656.
118. H.A. Abdel-Aziz, A.A.I. Mekawey, Stereoselective synthesis and antimicrobial activity of benzofuran-based (1E)-1-(piperidin-1-yl)-N2-arylamidrazones, Eur. J. Med. Chem. 44 (2009) 4985-4997.
119. S.V. Laxmi, B.S. Kuarm, B. Rajitha, Synthesis and antimicrobial activity of Coumarin pyrazole pyrimidine 2, 4, 6(1H, 3H, 5H) triones and thioxopyrimidine-4, 6(1H, 5H) diones, Med. Chem. Res. 22 (2012) 768-774.
120. R. Kenchappa, Y.D. Bodke, B. Asha, S. Telkar, M.A. Sindhe, Synthesis, antimicrobial, and antioxidant activity of benzofuran barbitone and benzofuran thiobarbitone derivatives, Med. Chem. Res. 23 (2014) 3065-3081.
121. D.W. Rodgers, S.J. Gamblin, B.A. Harris, S. Ray, J.S. Culp, B. Hellmig, D.J. Woolf, C. Debouck, S.C. Harrison, The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 1222-1226.
122. S.A. Galal, A.S. Abd El-Al, K.H. Hegab, A.A. Magd-El-Din, N.S. Youssef, H.I. El-Diwani, Novel antiviral benzofuran-transition metal complexes, Eur. J. Med. Chem. 45 (2010) 3035-3046.
123. Y. Malpani, R. Achary, S.Y. Kim, H.C. Jeong, P. Kim, S.B. Han, M. Kim, C.-K. Lee, J.N. Kim, Y.-S. Jung, Efficient synthesis of 3H, 3H-spiro [benzofuran-2, 10-isobenzofuran]-3, 3-dione as novel skeletons specifically for influenza virus type B inhibition, Eur. J. Med. Chem. 62 (2013) 534-544.
124. L. Huang, H. Miao, Y. Sun, F. Meng, X. Li, Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease, Eur. J. Med. Chem. 87 (2014) 429-439;
125. H.F. Kung, C.-W. Lee, Z.-P. Zhuang, M.-P. Kung, C. Hou, K. Plossl, Novel stilbenes as probes for amyloid plaques, J. Am. Chem. Soc. 123 (2001) 12740-12741.
126. W. Thies, L. Bleiler, Alzheimer's Association, 2013 Alzheimer's disease facts and figures, Alzheimers Dement. 9 (2013) 208-245;
127. H. Forstl, A. Kurz, Clinical features of Alzheimer's disease, Eur. Arch. Psychiatry Clin. Neurosci. 249 (1999) 288-290.
128. R. Christiane, Alzheimer's disease and the amyloid cascade hypothesis: a critical review, Int. J. Alzheimers Dis. 2012 (2012) 1-11;
129. S. Gandy, The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease, J. Clin. Invest 115 (2005) 1121-1129.
130. M. Jucker, L.C. Walker, Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders, Ann. Neurol. 70 (2011) 532-540;
131. J. Hardy, D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 297 (2002) 353-356.
132. J. Kaffy, D. Brinet, J.-L. Soulier, L. Khemtemourian, O. Lequin, M. Taverna, B. Crousse, S. Ongeri, Structure-activity relationships of sugar-based peptidomimetics as modulators of amyloid b-peptide early oligomerization and fibrillization, Eur. J. Med. Chem. 86 (2014) 752-758;
133. A. Jan, O. Gokce, R. Luthi-Carter, H.A. Lashuel, The ratio of monomeric to aggregated forms of Ab40 and Ab42 is an important determinant of amyloidb aggregation, fibrillogenesis, and toxicity, J. Biol. Chem. 283 (2008) 28176-28189;
134. P. Hammarstrom, R.L. Wiseman, E.T. Powers, J.W. Kelly, Prevention of transthyretin amyloid disease by changing protein misfolding energetic, Science 299 (2003) 713-716.
135. X.D. Cai, T.E. Golde, S.G. Younkin, Release of excess amyloid beta protein from a mutant amyloid beta protein precursor, Science 259 (1993) 514-516.
136. C. Airoldi, S. Mourtas, F. Cardona, C. Zona, E. Sironi, G. D'Orazio, E. Markoutsa, F. Nicotra, S.G. Antimisiaris, B.L. Ferla, Nanoliposomes presenting on surface a cis-glycofused benzopyran compound display binding affinity and aggregation inhibition ability towards amyloid b1-42 peptide, Eur. J. Med. Chem. 85 (2014) 43-50;
137. S. Salomone, F. Caraci, G.M. Leggio, J. Fedotova, F. Drago, Br. J. Clin. Pharm. 73 (2012) 504-517;
138. J.C. Vickers, T.C. Dickson, P.A. Adlard, H.L. Sounders, C.E. King, G. McCormack, The cause of neuronal degeneration in Alzheimer's disease, Prog. Neurobiol. 60 (2000) 139-165.
139. N. Jiang, S.-Y. Li, S.-S. Xie, Z.-R. Li, K.D.G. Wang, X.-B. Wang, L.-Y. Kong, Design, synthesis and evaluation of multifunctional salphen derivatives for the treatment of Alzheimer's disease, Eur. J. Med. Chem. 87 (2014) 540-551;
140. S. Fuse, K.M.Y. Fujita, H. Sugimoto, T. Takahashi, Development of dual targeting inhibitors against aggregations of amyloid-b and tau protein, Eur. J. Med. Chem. 85 (2014) 228-234;
141. M.S. Wolfe, M. Citron, T.S. Diehl, W. Xia, I.O. Donkor, D.J. Selkoe, A substrate-based difluoro ketone selectively inhibits Alzheimer's g-secretase activity, J. Med. Chem. 41 (1998) 6-9.
142. J.H. Byun, H.Y. Kim, Y.S. Kim, I.M.-Jung, D.J. Kim, W.K. Lee, K.H. Yoo, Aminostyryl benzofuran derivatives as potent inhibitors for Ab fibril formation, Bioorg. Med. Chem. Lett. 18 (2008) 5591-5593.
143. Y. Yang, M. Cui, Radiolabeled bioactive benzoheterocycles for imaging bamyloid plaques in Alzheimer's disease, Eur. J. Med. Chem. 87 (2014) 703-721;
144. D.J. Selkoe, Imaging Alzheimer's amyloid, Nat. Biotechnol. 18 (2000) 823-824.
145. C.A. Mathis, Y. Wang, W.E. Klunk, Imaging b-amyloid plaques and neurofibrillary tangles in the aging human brain, Curr. Pharm. Des. 10 (2004) 1469-1492.
146. A. Nordberg, PET imaging of amyloid in Alzheimer's disease, Lancet Neurol. 3 (2004) 519-527.
147. Y. Cheng, M. Ono, H. Kimura, S. Kagawa, R. Nishii, H. Kawashima, H. Saji, Fluorinated benzofuran derivatives for PET imaging of b-amyloid plaques in Alzheimer's disease brains, Med. Chem. Lett. 1 (2010) 321-325.
148. Y. Cheng, M. Ono, H. Kimura, S. Kagawa, R. Nishii, H. Saji, A novel 18F-labeled pyridyl benzofuran derivative for imaging of b-amyloid plaques in Alzheimer's brains, Bioorg. Med. Chem. Lett. 20 (2010) 6141-6144.
149. Y. Cheng, M. Ono, H. Kimura, M. Ueda, H. Saji, Technetium-99m labeled pyridyl benzofuran derivatives as single photon emission computed tomography imaging probes for b-amyloid plaques in Alzheimer's brains, J. Med. Chem. 55 (2012) 2279-2286.
150. K. Tsunoda, K. Abe, T. Hagino, K. Omata, S. Misawa, Y. Imai, K. Yoshinaga, Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension, Am. J. Hyperfens 6 (1993) 28-32.
151. J. Zhang, J.-L. Wang, W.-F. Yu, Z.-M. Zhou, W.-C. Tao, Y.-C. Wang, W.-Z. Xue, D. Xu, L.-P. Hao, X.-F. Han, F. Fei, T. Liu, A.-H. Liang, Nonpeptidic angiotensin II AT1 receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles, Eur. J. Med. Chem. 69 (2013) 44-54.
152. D. Middlemiss, G.M. Drew, B.C. Ross, M.J. Robertson, D.I.C. Scopes, M.D. Dowle, J. Akers, K.L. Clark, S. Coote, C.D. Eldred, J. Hamblett, A. HiIdltch, C.G. Hxst, A. Jac Ttravers, bromobenzofuran: a new class of potent, nonpeptide antagonists of angiotensin II, Bioorg. Med. Chem. Lett. 1 (1991) 711-716.
153. D.B. Judd, K.S. Cardwell, T.A. Panchal, T.I. Jack, M. Pass, T. Hubbard, A.W. Dean, A.U. Butt, J.E. Hobson, N.M. Heron, S.P. Watson, G.S. Currie, D. Middlemiss, D.G. Allen, N.M. Aston, J.M.S. Paton, G.M. Drew, A. Hilditch, D. Gallacher, M.K. Bayliss, M.C. Donnelly, et al., Benzofuran based nonpeptide antagonists of angiotensin II related to GR117289: part IV; Imidazopyridinylbenzofurans, Bioorg. Med. Chem. Lett. 4 (1994) 725-728.
154. G.S. Hassan, S.M. Abou-Seri, G. Kamel, M.M. Ali, Celecoxib analogs bearing benzofuran moiety as cyclooxygenase-2 inhibitors: design, synthesis and evaluation as potential anti-inflammatory agents, Eur. J. Med. Chem. 76 (2014) 482-493.
155. P. Yadav, P. Singh, A.K. Tewari, Design, synthesis, docking and antiinflammatory evaluation of novel series of benzofuran based prodrugs, Bioorg. Med. Chem. Lett. 24 (2014) 2251-2255.
156. R.A. Copeland, J.M. Williams, S. Giannaras, S. Nurnberg, M. Covington, D. Pinto, S. Pick, J.M. Trzaskos, Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase, Proc. Natl. Acad. Sci. U. S. A. 23 (1994) 11202-11206.
157. W.R. Pagels, R.J. Sachs, L.J. Marnett, D.L. Dewitt, W.L. Smith, Immunochemical evidence for the involvement of prostaglandin H synthase in hydroperoxidedependent oxidations by ram seminal vesicle microsomes, J. Biol. Chem. 258 (1983) 6517-6523.
158. R.W. Egan, J. Paxton, F.A. Kuehl Jr., Mechanism for irreversible selfdeactivation of prostaglandin synthetase, J. Biol. Chem. 251 (1976) 7329-7335.
159. C.A. Winter, E.A. Risely, G.W. Nuss, Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs, Proc. Soc. Exp. Biol. Med. 111 (1962) 544-547.
160. F.E. D'amour, D.L. Smith, A method for determining loss of pain sensation, J. Pharmacol. Exp. Ther. 72 (1941) 74-79.
161. J.J. Loux, P.D. DePalma, S.L. Yankell, Antipyretic testing of aspirin in rats, Toxicol. Appl. Pharmcol 22 (1972) 672-675.
162. O. Guardamagna, F. Abello, P. Saracco, V. Baracco, E. Rolfo, M. Pirro, Endothelial activation, inflammation and premature atherosclerosis in children with familial dyslipidemia, Atherosclerosis 207 (2009) 471-475.
163. A.S. Go, D. Mozaffarian, V.L. Roger, E.J. Benjamin, J.D. Berry, W.B. Borden, et al., Executive summary: heart disease and stroke statistics-2013 Update: a report from the American Heart Association, Circulation 127 (2013) 143-152.
164. G.I. Uwaifo, R.E. Ratner, Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk, Am. J. Cardiol. 99 (2006) 51-67;
165. R.K. Semple, V.K.K. Chatterjee, S. O'Rahilly, PPARg and human metabolic disease, J. Clin. Invest 116 (2006) 581-589.
166. R.L. Pollex, T.R. Joy, R.A. Hegele, Emerging antidyslipidemic drugs, expert opin, Emerg. Drugs 13 (2008) 363-381.
167. P.-H. Nguyen, T.-N.-A. Nguyen, T.-T. Dao, H.-W. Kang, D.-T. Ndinteh, J.-T. Mbafor, W.-K. Oh, AMP-Activated protein kinase (AMPK) activation by benzofurans and coumestans isolated from erythrina abyssinica, J. Nat. Prod. 73 (2010) 598-602.
168. T. Al-Qirim, G. Shattat, K. Sweidan, W. El-Huneidi, G. Abu Sheikha, K. Reema Abu, S. Hikmat, In vivo antihyperlipidemic activity of new series of N-(Benzoylphenyl) and N-(Acetylphenyl)-1-benzofuran-2-carboxamides in Rats, Arch. Pharm. 345 (2012) 401-406.
169. K.V. Sashidhara, R.K. Modukuri, R. Sonkar, K.B. Rao, G. Bhatia, Hybrid benzofuranebisindole derivatives: new prototypes with promising antihyperlipidemic activities, Eur. J. Med. Chem. 68 (2013) 38-46.
170. V.J. Ram, Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation, Prog. Drug Res. 60 (2003) 93-132;
171. M. Diamant, R.J. Heine, Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence, Drugs 63 (2003) 1373-1405.
172. B.P. Kennedy, Role of protein tyrosine phosphatase-1B in diabetes and obesity, Biomed. Pharmacother. 53 (1999) 466-470.
173. M. Dixit, B.K. Tripathi, A.K. Tamrakar, A.K. Srivastava, B. Kumar, A. Goel, Synthesis of benzofuran scaffold-based potential PTP-1B inhibitors, Bioorg. Med. Chem. 15 (2007) 727-734.
174. P.G. Wyatt, M.J. Allen, J. Chilcott, C.J. Gardner, D.G. Livermore, J.E. Mordaunt, F. Nerozzi, M. Patel, M.J. Perren, G.G. Weingarten, S. Shabbir, P.M. Woollard, P. Zhou, Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives, Bioorg. Med. Chem. Lett. 12 (2002) 1405-1411.
175. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, T. Masaki, A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature 332 (6163) (1988) 411-415.
176. M. Roh, S.A. Abdulkadir, Targeting the endothelin receptor in prostate cancer bone metastasis: back to the mouse Cancer Biol. Ther. 9 (8) (2010) 615-617.
177. A.B. Skalska, T. Grodzicki, Carotid atherosclerosis in elderly hypertensive patients: potential role of endothelin and plasma antioxidant capacity, J. Hum. Hypertens. 24 (2010) 538-544.
178. A. Jacobs, I.R. Preston, M.G.-Maitland, Endothelin receptor antagonism in pulmonary arterial hypertension-a role for selective ET(A) inhibition Curr. Med. Res. Opin. 22 (2006) 2567-2574.
179. T. Masaki, J.R. Vane, P.M. Vanhoutte, International union of pharmacology nomenclature of endothelin receptors, Pharmacol. Rev. 46 (1994) 137-142.
180. J.S. Kaltenbronn, J. Quin, B.R. Reisdorph, S. Klutchko, E.E. Reynolds, K.M. Welch, M.A. Flynn, A.M. Doherty, Benzofuran derivatives as ETAselective, non-peptide endothelin antagonists, Eur. J. Med. Chem. 32 (1997) 425-431.
181. J. Cai, J. Chen, M. Cao, P. Wang, C. Feng, M. Ji, Design, synthesis, and biological evaluation of benzofuran derivatives as ET receptor antagonists, Med. Chem. Res. 22 (2013) 5472-5480.
182. S.H. Yuan, D.Z. Dai, L. Guan, Y. Dai, M. Ji, CPU0507, an endothelin receptor antagonist, improves rat hypoxic pulmonary artery hypertension and constriction in vivo and in vitro, Clin. Exp. Pharmacol. Physiol. 33 (2006) 1066-1072.
183. T. Ohishi, S. Yoshida, The therapeutic potential of GPR119 agonists for type 2 diabetes, Expert Opin. Investig. Drugs 21 (2012) 321-328;
184. Jones, J.N. Leonard, The emergence of GPR119 agonists as antidiabetic agents, Annu. Rep. Med. Chem. 44 (2009) 149-170.
185. L. Lan, H.V. Lin, C.F. Wang, M.J. Wright, S. Xu, L. Kang, K. Juhl, J.A. Hedrick, T.J. Kowalski, Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways, Br. J. Pharmacol. 165 (2012) 2799-2807.
186. G. Semple, B. Fioravanti, G. Pereira, I. Calderon, J. Uy, K. Choi, Y. Xiong, A. Ren, M. Morgan, V. Dave, W. Thomsen, D.J. Unett, C. Xing, S. Bossie, C. Carroll, Z. Chu, J. Leonard, R.M. Jones, Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119, J. Med. Chem. 51 (2008) 5172-5175.
187. H.A. Overton, M.C.T. Fyfe, C. Reynet, GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity, Br. J. Pharmacol. 153 (2008) S76-S81.
188. G. Semple, J. Lehmann, A. Wong, A. Ren, M. Bruce, Y.-J. Shin, C.R. Sage, M. Morgan, W.-C. Chen, K. Sebring, Z.-L. Chu, J.N. Leonard, H. Al-Shamma, A.J. Grottick, F. Du, Y. Liang, K. Demarest, R.M. Jones, Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile, Bioorg. Med. Chem. Lett. 22 (2012) 1750-1755;
189. Thomas Pharma® drug report (http://drugnews.thomsonpharma.com/ddn/home.do);
190. C. McWherter, in: The 32nd Annual National Medicinal Chemistry Symposium, Minnesota, MN, June 6-9, 2010 oral session 2;
191. A.J. Carpenter, in: The 32nd Annual National Medicinal Chemistry Symposium, Minnesota, MN, June 6-9, 2010 oral session 2;
192. PSN821 Structure Has Not Been Disclosed. Its Close Lead PSN408 Was Disclosed, See the 32nd Annual National Medicinal Chemistry Symposium, Minnesota, MN, June 6-9, 2010 oral session 2.
193. L.B. Katz, J.J. Gambale, P.L. Rothenberg, S.R. Vanapalli, N. Vaccaro, L. Xi, D.C. Polidori, E. Vets, T.C. Sarich, P.P. Stein, Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects, Clin. Pharmacol. Ther. 90 (2011) 685-692;
194. L.B. Katz, J.J. Gambale, P.L. Rothenberg, S.R. Vanapalli, N. Vaccaro, L. Xi, T.C. Sarich, P.P. Stein, Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes, Diabetes Obes. Metab. 14 (2012) 709-716.
195. X.-Y. Ye, C.L. Morales, Y. Wang, K.A. Rossi, S.E. Malmstrom, M. Abousleiman, L. Sereda, A. Apedo, J.A. Robl, K.J. Miller, J. Krupinski, Synthesis and structureeactivity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists, Bioorg. Med. Chem. Lett. 24 (2014) 2539-2545.
196. D. Kellerman, R. Evans, D. Mathews, C. Shaffer, Inhaled P2-2 receptor agonists as a treatment for patients with cystic fibrosis lung disease, Adv. Drug Deliv. Rev. 54 (2002) 1463-1473.
197. B. Hechler, M. Cattaneo, C. Gachet, The P2 receptors in platelet function, Semin. Thromb. Hemost. 312 (2005) 150-161.
198. G.L. Plosker, K.A.L.-Williamson, Clopidogrel, Drugs 67 (2007) 613-646.
199. J.L. Boyer, M. Adams, R.G. Ravi, K.A. Jacobson, T.K. Harden, 2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3', 5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist, Br. J. Pharmacol. 135 (2002) 2004-2010.
200. C. Leon, M. Freund, C. Ravanat, A. Baurand, J.P. Cazenave, C. Gachet, Key role of the P2-1 receptor in tissue factoreinduced thrombin-dependent acute thromboembolism : studies in P2-1-knockout mice and mice treated with a P2-1 antagonist, circulation 103 (2001) 718-723.
201. R.K. Thalji, N. Aiyar, E.A. Davenport, J.A. Erhardt, L.A. Kallal, D.M. Morrow, S. Senadhi, C.L. Burns-Kurtis, J.P. Marino Jr., Benzofuran-substituted urea derivatives as novel P2-1 receptor antagonists, Bioorg. Med. Chem. Lett. 20 (2010) 4104-4107.
202. J. Chun, H. Hartung, Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis, Clin. Neuropharmacol. 33 (2010) 91-101.
203. L. Kappos, E.-W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, L.Z.-Auberson, P.A. Burtin, Placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis, N. Engl. J. Med. 362 (2010) 387-401.
204. H. Kataoka, K. Sugahara, K. Shimano, K. Teshima, M. Koyama, A. Fukunari, K. Chiba, FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T Cell infiltration, Cell. Mol. Immunol. 2 (2005) 439-448.
205. T. Baumruker, A. Billich, V. Brinkmann, Translation of a novel mechanism into clinical benefit in multiple sclerosis, Expert Opin. Invest. Drugs 16 (2007) 283-289.
206. K. Chiba, H. Matsuyuki, Y. Maeda, K. Sugahara, Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus, Cell. Mol. Immunol. 3 (2006) 11-19.
207. D. Verzijl, S.L.M. Peters, A.E. Alewijnse, Sphingosine-1-phosphate receptors: zooming in on ligand-induced intracellular trafficking and its functional implications, Mol. Cells 29 (2010) 99-104.
208. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, K.T.-Wilck, A. de Vera, J. Jin, T. Stites, S. Wu, S. Aradhye, L. Kappos, TRANSFORMS Study Group, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N. Engl. J. Med. 362 (2010) 402-415.
209. J.M. Kovarik, M. Lu, G. Riviere, I. Barbet, S. Maton, D.R. Goldwater, R.L. Schmouder, The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects, Eur. J. Clin. Pharmacol. 64 (2008) 457-463.
210. A.K. Saha, X. Yu, J. Lin, M. Lobera, A. Sharadendu, S. Chereku, N. Schutz, D. Segal, Y. Marantz, D. McCauley, S. Middleton, J. Siu, R.W. Bürli, J. Buys, M. Horner, K. Salyers, M. Schrag, H.M. Vargas, Y. Xu, M. McElvain, H. Xu, Benzofuran derivatives as potent, orally active S1-1 receptor agonists: a preclinical lead molecule for MS, Med. Chem. Lett. 2 (2011) 97-101.